SLS
NASDAQ · Biotechnology
Sellas Life Sciences Group I
$8.05
+0.29 (+3.74%)
Open$8.05
Previous Close$7.76
Day High$8.38
Day Low$7.91
52W High$9.51
52W Low$1.39
Volume—
Avg Volume6.62M
Market Cap1.50B
P/E Ratio—
EPS$-0.23
SectorBiotechnology
Analyst Ratings
Strong Buy
6 analysts
Price Target
+321.1% upside
Current
$8.05
$8.05
Target
$33.90
$33.90
$25.20
$33.90 avg
$43.49
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 353.66M | 369.01M | 305.89M |
| Net Income | 19.39M | 21.88M | 20.34M |
| Profit Margin | 5.5% | 5.9% | 6.7% |
| EBITDA | 24.66M | 25.78M | 21.04M |
| Free Cash Flow | 20.13M | 23.20M | 18.29M |
| Rev Growth | -7.4% | -1.2% | +17.7% |
| Debt/Equity | 0.38 | 0.40 | 0.41 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |